Entweder 10000% oder Totalverlust

oh je natürlich 30000 in Aktien.Neureich will man doch erst werden.
Ja W-o ist auch ein Forum wallstreet-online.Aber vorsicht lerne erstmal die leute da kennen.Das Ding steckt voller Bagaluden wie z.b. hairman alias hairman2000,alias starsailor und und und.Ich habe diese Forum als Nr 1 schätzen gelernt,weil hier nicht immer aber immer öfter die Wahrheit gesprochen wird.Die Tips sind hier auch mehr an der Realität.W-o ist ein reines Zocker forum(meine Meinung).
Hoffe ich bekomme jetzt keine drohmails.(hihihooo)  

30000 in Aktien oder 30000 Aktien, jetzt drück dich doch bitte endlich mal prezise aus ;-)!!!

 

http://finance.lycos.com/home/news/...bols=NASDAQ:OSUR&story=31267198
The new AIDS test, called OraQuick and made by OraSure
Technologies Inc. (NASDAQ:OSUR), had 99.6 percent accuracy from
testing a drop of blood drawn from a finger and was simple to
use, the Food and Drug Administration said. OraSure's stock
jumped more than 20 percent to $7.46 on the Nasdaq on Friday.

    The OraQuick test will be useful for identifying
HIV-positive pregnant women going into labor, providing the
chance for treatment to prevent infections in their newborns.

The test also will help determine quickly when health care
workers are accidentally exposed to infected blood  

OraSure Technologies (OSUR: sentiment, chart, options) is a pharmaceutical concern that developed the OraQuick test with Abbott Laboratories. This new technology, which can determine the presence (or absence) of HIV in around 20 minutes, was recently approved by the Food and Drug Administration. Yesterday, OSUR applied to the FDA for a waiver for the OraQuick product. The waiver would allow the test to be distributed to certain sites in the United States, including clinics and doctors' offices. OSUR shares have risen more than 16 percent today on above average volume. The stock has hurdled the 6.50 level, which provided short-term resistance since mid-November. Options players have failed to take an interest in OSUR; in the front three-month series, there are currently only 2,143 open calls and 167 open puts. Short sellers, on the other hand, have sold nearly 1.7 million OSUR shares short, causing a short-interest ratio of 12.5 times.

 

30000 anteile zu 0,055 euro hatte ich mir ins Depot gelegt.Also net so viel.Ach mal ne Frage an @Kicky.was hat Osur mit Caly zu tun?  

wenn grenkes Einschätzung stimmt!

Euer masteruz  

ich würde gerne kaufen, aber ich trau mich nicht....
gehts morgen nach oben?.......  

gehts ganz sicher nach oben, denn die haben ja noch Nacholbedarf, nachdem Freitag nach Handelsschluss die Aktie in den USA nochmals um über 18% zugelegt hat! Also laufen wir morgen vormittag sicher gegen 0,08€ (vielleicht auch schon zum Handelsauftakt)! Und der weitere Weg entscheidet sich dann um 15:30 Uhr, wenn die Amis anfangen! Wobei ich denke, dass es bis zum 14.02. noch ganz schön bergauf gehen könnte!!!

Am besten morgen nochmal auf einen kleinen Rücksetzer hoffen (könnte aber auch ausbleiben) und dann zuschlagen!

Gruß masteruz  

UPDATE 2-Bush widens access to quick AIDS test
31 Jan 2003, 11:35pm ET

WASHINGTON, Jan 31 (Reuters) - President George W. Bush
cleared the way on Friday for providing wide access to new AIDS
tests that can deliver results in minutes, and promised a big
increase in domestic funding for AIDS prevention.

   Bush said the Health and Human Services Department had
waived restrictions on a new rapid AIDS test, making it
available for use in more than 100,000 doctors' offices across
the country.

   The test, which provides results in about 20 minutes, is
needed because every year an estimated 8,000 infected people go
to clinics for testing but do not return a week later for the
results.

   "How can you treat if you don't test? How can you help if
you don't know?" Bushed asked in a speech after meeting his
advisory council on HIV/AIDS.

   Under fire from AIDS groups for what they call his neglect
of the disease, Bush asked Congress on Tuesday to triple AIDS
spending in Africa and Haiti to $15 billion over five years.

   On Friday, he said he was proposing $16 billion for AIDS
prevention and treatment in the United States in the 2004
fiscal year, a 7 percent increase over current funding.

   AIDS groups welcomed the move.

   "We trust that it will be spent on a comprehensive
approach, including safer-sex and abstinence, and will be
specifically tailored to the issues of the post-antiretroviral
era," Dr. Jose Zuniga, president of International Association
of Physicians in AIDS Care, said in a statement.

   "The $100 million increase to the AIDS Drug Assistance
Program means that many more uninsured Americans will have
access to life-prolonging antiretroviral drugs; this
much-needed money represents a second chance at life for
Americans with HIV/AIDS."
   More than 36 million people are infected with the virus
that causes AIDS -- 25 million in Africa alone.

   An estimated one-quarter of the estimated 900,000
HIV-positive people in the United States do not know they are
infected with the virus, according to the Centers for Disease
Control and Prevention.

   Finding out enables them to seek treatment and take steps
to avoid spreading the virus.

   There is no cure, but a cocktail of expensive drugs known
as antiretrovirals can keep the disease at bay.

   The new AIDS test, called OraQuick and made by OraSure
Technologies Inc. (NASDAQ:OSUR), had 99.6 percent accuracy from
testing a drop of blood drawn from a finger and was simple to
use, the Food and Drug Administration said. OraSure's stock
jumped more than 20 percent to $7.46 on the Nasdaq on Friday.

    The OraQuick test will be useful for identifying
HIV-positive pregnant women going into labor, providing the
chance for treatment to prevent infections in their newborns.

The test also will help determine quickly when health care
workers are accidentally exposed to infected blood.


Copyright 2003, Reuters News Service
 

also mal abwarten was jetzt passiert.


gruß grenke  

ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 27, 2003--Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the   O N L Y   two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, today announced that a recent study from The Johns Hopkins University utilized Calypte's HIV-1 EIA and Western Blot Urine tests to determine that urine-based HIV screening is effective.

 

Calypte Comments On President Bush's Plans for AIDS Relief; Calypte's Safe Blood for Africa Relationship Focuses on HIV Testing

ALAMEDA, Calif., Feb 3, 2003 (BUSINESS WIRE) -- Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, commented on President George W. Bush's January 31, 2003 speech. His remarks outlined a plan he has submitted to Congress to devote $15 billion toward fighting AIDS via prevention education, testing and treatment.
Tony Cataldo, chairman of Calypte, stated, "Calypte is thrilled with the President's commitment to combat the global AIDS epidemic. We believe the President's agenda reinforces the need for a safe, inexpensive testing device, especially in global communities currently facing AIDS in epidemic proportions. Calypte is seeking to make inroads in several markets, including China and Africa. Recently, we announced our relationship with Safe Blood for Africa Foundation to market and distribute Calypte's urine-based HIV-1 antibody tests in sub-Saharan Africa as a blood donor pre-screening tool. By pre-screening blood donors with urine tests, the foundation can save money and resources, money which can be applied to expanding our coverage and services."

In the remarks on fighting global and domestic HIV/AIDS, President Bush stated that the US Department of Health and Human Services has approved a CLIA (Clinical Laboratory Improvements Amendments) waiver for a rapid blood test currently on the market that provides HIV-1 test results in just 20 minutes.

"The CLIA waiver approval bodes well for all rapid HIV testing products, as it clears the way for moving HIV testing into the field, including emergency rooms, outreach clinics, community-based organizations and physicians' offices," stated Nancy Katz, president and CEO of Calypte. "We believe the FDA has now set a precedent by waiving the requirement for laboratory involvement for a rapid blood test. Our goal is to obtain approval for the Calypte Rapid HIV Urine Test, which will provide similar accuracy and time-to-results in a much safer and less expensive format."

"Our recent experience with the FDA indicates to us that the current administration has a renewed sense of urgency regarding HIV/AIDS related science. We believe the Bush administration will move quickly to review and make available additional rapid tests, especially those based on bodily fluids other than blood," continued Katz.

Calypte is in the process of preparing its FDA Investigational Device Exemption (IDE). Senior Calypte management met with representatives of FDA's Center for Biologics Evaluation and Research (CBER) on October 4, 2002 to review plans for the IDE submission. After completion of US clinical studies, Calypte will be filing its Rapid HIV Urine Test by using a modular pre-market approval (PMA) application approach. After receiving PMA approval, Calypte will file for approval of a CLIA waiver Calypte is filing its Rapid HIV Urine Test by using a modular pre-market approval (PMA) application approach. After receiving PMA approval, Calypte will file for a CLIA waiver.

About Calypte Biomedical

Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found on our website at www.calypte.com.

About Safe Blood for Africa Foundation

The Safe Blood for Africa Foundation is a not-for-profit corporation whose mission is to help prevent the spread of HIV/AIDS throughout 34 countries in sub-Saharan Africa. The organization is working with such groups as the World Bank, USAID, UNAIDS, and the World Health Organization (WHO). The Safe Blood for Africa Foundation estimates that of the 6 million blood transfusions performed annually in sub-Saharan Africa, approximately half of the transfused materials have not been tested for infectious diseases. As the Safe Blood for Africa Foundation's testing responsibility grows to cover all of sub-Saharan Africa, the number of blood transfusions performed is anticipated to grow to 12 million transfusions per year. The Safe Blood for Africa Foundation estimates that less than half of sub-Saharan African countries have adopted a national blood transfusion policy and less than one third of the countries have policies to limit HIV infection through blood transfusions. Since the HIV prevalence in many of these countries exceeds 20%, blood transfusions account for an ever-increasing cause of new infections.

Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2001 and its subsequent filings with the SEC.



CONTACT:          Calypte Biomedical Corporation
                 Nancy Katz, President & CEO, 510/749-5100
                 nkatz@calypte.com
                 or
                 Lippert/Heilshorn & Associates
                 Investor Relations Contact:
                 Brendan Lahiff/Kirsten Chapman, 415/433-3777
                 brendan@lhai-sf.com


 

Langfristig halte ich natürlich an meinem Kursziel fest, obwohl das ja jetzt etwas schwieriger ist, da die Aktienzahl im mom bei 200mio liegt, und mein Kursziel galt als noch ein Bestand von 60mio vorlag.
gruß grenke  

 

Wenn erst die amerikanischen Märkte eröffnen gehts mit Sicherheit noch mal um eine zweistellige Prozentzahl nach oben (Ziel: 10 Cent; Grenke du hattest recht!!!)! Denn die offizielle Stellungnahme von Calypte zu Bushs Anti-AIDS Kampagne gab's ja  erst heute morgen!

 

dass ich einer Empfehlung aus diesem Forum gefolgt bin.

Grenke, danke schon mal.....wie lange läßt Du laufen?  

was ich wohl machen werde, und auch jedem raten würde, sollte sich das Papier gut entwickeln unbedingt einen Stop-Kurs zu setzten, wobei jeder für sich selbst endscheiden sollte wo dieser gesetzt wird.

Meinen ersten stop werde ich wahrscheinlich setzten bei Kursen über 1€.
Werde aber auf jeden fall vorher bescheid sagen.


gruß grenke  

denke die werden wir auch sehen, falls positiv für Caly endschieden wird.

Langfristig halte ich immer noch die 16€ für ereichbar.


gruß grenke  

... allerdings bin ich bei weit höheren Kursen reingegangen. Ich werd meine erste Position bei 1 Euro abgeben u. meine zweite Position bleibt drin, als Langfristanlage.

Grenke könnte bei seinem Kursziel tatsächlich sehr nahe dran liegen.

Jeder sollte ein paar Calypte im Depot haben.  

 

habe nicht vor das ding hier zu pushen, was andereseits auch gar nicht möglich ist da die Kurse in den USA gemacht werden.

was ich aber super interessant finde, das es doch nu wirklich möglich ist mit einer Aktie die fast nichts mehr wert ist reich zu werden, vorausgestzt man hat den mut ein paar Kröten eventuell auch in den sand zu setzten.( EM-TV bestes beispiel)

alles oder nichts heißt es hier, wenn Kicky recht hat ist die Kohle futsch, liegt sie falsch dann winken hier ne menge Prozente denke ich.

gruß grenke  

 

0,09 in Frankfurt!

Bid: 0,09
Ask: 0,091

Gruß masteruz

P.S.: Ich glaub nicht, dass die Amis uns heute hängen lassen!!!  

bei 0,089, die 100 Tage Linie ist greifbar!!!

Gruß masteruz